U. S. SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549
                                  FORM 10-KSB/A

  |X| Annual report under section 13 or 15(d) of the Securities Exchange Act of
                1934 for the fiscal year ended December 31, 2004

 |_| Transition report under section 13 or 15(d) of the Securities Exchange Act
               of 1934 for the transition period from _________to

                        Commission File Number: 000-23039

                              ORALABS HOLDING CORP.


                 (Name of small business issuer in its charter)



              Colorado                                           14-1623047
--------------------------------------------                --------------------
(State or other jurisdiction of                               (I.R.S. Employer
 incorporation or organization)                              Identification No.)

18685 East Plaza Drive, Parker, Colorado                            80134
--------------------------------------------                --------------------
 (Address of principal executive offices)                         (Zip Code)


                   (Issuer's telephone number: (303) 783-9499

              Securities registered under Section 12(b) of the Act:



    Title of each class                                  Name of each exchange
           None                                          on which registered
--------------------------------------------


              Securities registered under Section 12(g) of the Act:

                    Common Shares, par value $0.001 per share
                                (Title of class)

Check whether the issuer (1) filed all reports required to be filed by
Section 13 or 15(d) of the Securities Exchange Act during the past 12 months (or
for such shorter period that the registrant was required to file such reports),
and (2) has been subject to such filing requirements for the past 90 days. Yes X
No___

Check if there is no disclosure of delinquent filers in response to Item
405 of Regulation S-B is not contained in this form and no disclosure will be
contained, to the best of registrant's knowledge, in definitive proxy or
information statements incorporated by reference in Part III of this Form 10-KSB
or any amendment to this Form 10-KSB. ___

State issuer's revenues for its most recent fiscal year: $13,130,579
<PAGE>


As of April 4, 2005, the aggregate market value of common stock held by
non-affiliates of the Registrant, computed by reference to the last trade of the
common stock on that date was approximately $2,586,317.

(Issuers involved in bankruptcy proceedings during the past five years)
Check whether the issuer has filed all documents and reports required to be
filed by Section 12, 13 or 15(d) of the Exchange Act after the distribution of
securities under a plan confirmed by a court. Yes ___ No ___

(Applicable only to corporate registrants) State the number of shares
outstanding of each of the issuer's classes of common equity, as of the latest
practicable date. As of April 4, 2005, there were 4,668,615 shares of common
stock outstanding.


Transitional Small Business Disclosure Format (Check one):

                                  Yes ___ No X


EXPLANATORY NOTE

     This Amendment to our Annual Report on Form 10-KSB amends our Annual Report
on Form 10-KSB for the fiscal year ended December 31, 2004, that was originally
filed on April 18, 2005. In addition to non-substantive corrections of
typographical errors, grammar, and presentation, and except for immaterial
corrections of figures, the following items have been amended:

1.   In Part I, Item 6, several changes were made to clarify the text of the
     Liquidity and Capital Resources section.

2.   In Part I, Item 6, text was revised in the Trends section and a table was
     inserted to show aggregated information about contractual obligations as of
     December 31, 2004.

3.   In Part I, Item 8-A, certain references to "deficiencies" were revised to
     refer to "reportable conditions".

4.   The description of Exhibit 11 in the exhibit list included in Part III,
     Item 13(a)(2) was revised.

5.   We revised some figures in the "non-current assets" and "non-current
     liabilities" entries of the Consolidated Balance Sheet.

6.   The Consolidated Statements of Operations was correctly denominated in the
     Financial Statements and certain descriptive portions of the Consolidated
     Statements of Operations were revised.

7.   In the section "Basic and Diluted Earnings (Loss) Per Common Share" of Note
     1 of the Financial Statements, text was deleted from the subsection
     entitled "Basic Loss Per Share" and figures were corrected in the table
     included in the subsection entitled "Stock-Based Compensation".

8.   We deleted and replaced the text of the Litigation section in Note 6 to the
     Financial Statements.

9.   Note 9 to the Financial Statements was renamed "Definitive Agreement" and
     the text of that Note was revised.

10.  We added Note 13 to the Financial Statements to describe our 401(k) plan

11.  Exhibits 23.1, 31.1, 31.2, 32.1 and 32.2 were updated.

12.  Except for the changes listed above, this Form 10-KSB/A does not modify or
     update in any material respect other disclosures in, or exhibits to, the
     filed Form 10-KSB. This Amendment continues to speak as of the date of the
     original Annual Report, and we have not updated the disclosure contained
     herein to reflect events that have occurred since the filing of the
     original Annual Report.
<PAGE>
                                     PART I

Business Development. On May 1, 1997, OraLabs, Inc., a privately held
company, became a wholly owned subsidiary of SSI Capital Corp. (the predecessor
of the Company). SSI Capital Corp. subsequently merged with OraLabs Holding
Corp., with OraLabs Holding Corp. becoming the surviving company. As a result of
these transactions, the Company is the sole stockholder of OraLabs, Inc. The
term "Company" or "OraLabs" will mean OraLabs Holding Corp., successor to SSI
Capital Corp., and except where otherwise indicated, all discussions of the
business of the Company includes the business of OraLabs, Inc. (the
"Subsidiary").

The Subsidiary was formed in 1990 for the purposes of manufacturing and
distributing tooth-whitening products. In 1992, in order to expand the product
line, the Subsidiary's developed what became known as its flagship product, Ice
Drops(R). Ice Drops are breath drop product sold in a small plastic bottle and
introduced as an alternative to breath sprays and candy breath mints.

In 1999, the Company introduced its own brands of lip balm in traditional
twist stick containers. The brands currently being marketed consist of Essential
Lip Moisture, Lip Naturals(R), Chap Ice(R), Soothe & Shine(R), and Lip Rageous
(R). These brands are sold in traditional twist up containers and the Company's
patented mini-container, which was introduced in 1996. The Company also sells
lip balms and glosses in unique new containers and hopes to be able to continue
to distinguish itself from competition by innovative packaging.

In 2003, the Company acquired certain assets of Symbiosis, Inc. These
assets included, but were not limited to, intellectual property consisting of
trade names Leashables(R) and Chapgrip(R) and a patent for a lip balm holder.

The nutritional supplement brands contribute less than 5 % of the Company's
revenues. The Company is not planning any material changes to this part of the
business.

In addition, the Company has engaged in negotiations with other businesses
and from time to time contacts persons involved in corporate finance matters to
determine if there are businesses interested in a merger or other acquisition of
or combination with the Company.

As previously announced by the Company in its Form 8-K filed on February
23, 2005, OraLabs entered into a Definitive Agreement with NVC Lighting
Investment Holdings Limited under which OraLabs will acquire NVC and convey its
ownership of OraLabs, Inc. to OraLabs' President, Gary H. Schlatter. Control of
the Company would change from Mr. Schlatter to the owners of NVC. Closing under
the Definitive Agreement is conditioned upon many requirements and there can be
no assurance that the closing will occur. If the parties do not otherwise
terminate the Definitive Agreement, then OraLabs, in anticipation of a meeting
of its shareholders called to approve the transactions, will file with the
Securities and Exchange Commission a Proxy Statement that will include more
detailed information about the Definitive Agreement and the proposed
transactions.

Business of the Company.
------------------------

Principal Products, Their Markets and Distribution. The general business of
the Company is to produce and sell consumer products relating to oral care and
lip care and to distribute nutritional supplements. The Company's products are
currently sold in the USA nationally as well as numerous foreign countries. The
products are sold through wholesale distributors as well as by direct sale to
mass retailers, grocery stores, convenience stores and drug stores. The
principal products produced by the Company can be categorized into three groups:
breath fresheners, including liquid drops and sprays under the brand name Ice
Drops((R)) and Sour Zone((TM)M) brand sour drops and sour sprays; lip balm
products under the names Lip Rageous((R)), Chap Ice((R)), Lip Naturals((R)), Lip
Rageous Glitters(TM), Essential Lip Moisture and Soothe & Shine((R)), as well as
private label names, promotional products under the name Leashables (R),and
nutritional supplement products consisting of 5-HTP and Cheat & Lean(R).

In general, the Company's distribution still covers the same markets that
it always has, although 2004 saw an increase in the promotional products
markets. As has been the case in recent years, sales and promotional expenses
were predominantly to large retailers. The Company believes that the lip balm
category will continue to be the Company's primary business. The Company has
established itself as a viable competitor in the lip balm business, deriving
approximately 80% of its revenue from this category. This is a category that the
Company believes can grow in sales. However, it is possible that competitive
pressures could further erode margins and increase promotional costs and selling
expenses for the Company.

The sales of breath freshener and sour candies remained stable in year
2004. Convenience store and vending distribution has stayed somewhat stable,
while dollar store distribution has varied significantly from year to year. This
market remains very important and viable to the future of the Company. The
Company's distribution network provides continual opportunities for sales of its
breath freshening and sour candies products.

The Company's strategy for its breath freshener and lip balm products has
been to establish name brands and to develop and sell products that fill niches.
The price/value marketing strategy includes capitalizing on the distribution
network that currently carries one or more of the Company's products, and
building upon the business relationships that have been established.

The Company believes that nutritional supplement sales will remain less
than 5% part of its overall revenue. The Company is not planning any material
changes to its nutritional supplement marketing plan.

The Company's products and packaging continue to be conceptualized and
developed in-house. The Company's breath freshener and lip balm products are
marketed from and packaged at the Company's manufacturing facility in Parker,
Colorado. Most packaging, filling and automated manufacturing equipment has been
designed, built and maintained by the Company's own staff. This allows the
Company to rapidly introduce and manufacture new products, reducing lengthy lead
times and some of the cost of capital expenditures associated with some new
product introductions. It also allows the Company to test new products before
committing capital to full-scale manufacturing endeavors. However, the Company
has purchased some high speed filling and labeling equipment in order to help
with capacities for well established products.

Products Launched in 2004. The Company did not add any material new
products. However, brand extensions with different types of innovative, creative
packaging were added.

                                     Page 1
<PAGE>

Competitive Business Conditions. Competition from major branded competitors
in the mass retail segment as well as private label manufacturing continues to
be very significant.

With respect to the Company's breath freshening products, direct
competitors who manufacture liquid or spray breath products consist of less than
five. Breath mints and breath strips are a significant competitive force and
continue to dominate shelf space in retail storefronts. The Company believes
that there are more than 50 competitors in the category. The breath freshening
category is always filled with numerous new product introductions from large
competitors.

With respect to the Company's lip balm products, the Company believes that
approximately 70% of the market is controlled by three dominant competitors (who
sell Chapstick(R), Blistex(R) and Carmex(R), and the balance of the market
consists of more than 50 different brands. It is estimated that there are only
ten to twenty viable competitors from a manufacturing standpoint. Most of the
competitors are also trying to introduce new products as a means of growth and
market share. The retail stores have a finite amount of space, so getting new
slots in retail stores is a challenge.

The Company has sought to distinguish itself by size and packaging of its
products, as well as by competing with respect to pricing. The Company believes
that for some of its products, its smaller size and lower price than that of its
competitors is an advantage to the Company. However, other factors such as a
competitor's greater brand recognition or preferable product placement of a
competitor's products at retail locations may nullify or reduce whatever
competitive advantage the Company's products have. Strong national brands are
very difficult to displace and compete against. The price/value positioning and
niche marketing opportunities are where the Company is focused.

With respect to nutritional supplement products, competition in this
industry is very broad based. The Company has followed its strategy of
maintaining a very narrowly focused effort for the products that it has
determined to be financially viable. The Company determined that a broad base in
this category is not a part of its plan at this time. It is also the Company's
expectation that there will also be more and tighter regulation by the
government in the future, making it more expensive to do business in this
segment (see "Government Regulation" below).

Sources and Availability of Raw Materials. In general, the sources and
availability of materials used by the Company in its business are fairly
widespread, and the Company believes that it could obtain secondary sources of
raw materials at comparable prices to the extent that an existing business
relationship terminates.

Dependence upon a Single Customer. The Company does not believe that its
business with respect to any particular product or products is dependent upon
any single customer. However, the Company had two major customers that accounted
for approximately $1,950,000 and $1,400,000 respectively, or 15% and 11% of net
sales for the year 2004. The Company is always at risk of its customers filing
for bankruptcy or liquidation or being dropped by a major customer. This has
happened in the past and could happen again in the future.

Patents, Trademarks, Licenses, Franchises and Concessions. Although there
can be no assurance of proprietary protection respecting pending patents,
patents and trademarks held by the Company (see, "Cautionary Statement Regarding
Forward-Looking Statements, No Assurance of Proprietary Protection"), and
although the Company intends to vigorously seek to enforce and protect its
proprietary rights, the Company does not believe that the loss of any such
proprietary right would in and of itself, adversely affect the Company in a
material manner.

Seasonality. The demand for the Company's lip balm products tends to
increase during the cold, dry weather months, but the inclusion of sun block in
some of the lip balm products may help to offset some of the seasonality. Even
though the sun block products help, sales of lip balm are still considered to be
50-70% seasonal.

Practices of the Company in the Industry. The Company's typical plans with
respect to all of its products are to keep adequate inventory on hand for
shipments within the required time frame to meet orders. The Company generally
extends credit on purchases for a term of 30-90 days after shipment. The Company
does not typically formally provide a right of customers to return merchandise.
However, the Company believes that it is a common practice in the industry, and
the Company subscribes to such practice on a case-by-case basis, to permit a
retailer who has not sold all of the goods it has purchased within a reasonable
time, to ask the Company to accept a return of the unsold merchandise. The
Company estimates and records a reserve for returns upon sale. The Company also
expects, as it is common practice in the industry, for retailers to take
deductions for "un-saleable product", which are its products that have either
been returned by a customer to the retailer or for which the packaging has
somehow become un-saleable in the retailer's sole discretion.

                                     Page 2
<PAGE>

Managing Manufacturing Requirements. The Company has done several things to
position itself for stability in 2005. In positioning for stability and
profitability, the Company has made changes to management, customer service,
manufacturing, and sales and administrative personnel. These changes have come
at costs that have put the Company in an unprofitable position for the year. The
Company has been in its new facility since February of 2004. The extra space has
helped to allow the Company to more efficiently process its orders. However the
associated costs with the new facility have not yet been offset by increased
revenues. The Company plans to reduce its product offerings in order that it
will be able to lower its cost to produce fewer product offerings. The Company
hopes to be able to return to a state of profitability, however there are no
assurances that it will happen. See Trends section in Management Discussion and
Analysis.

Government Regulation. The manufacturing, packaging, processing,
formulation, labeling, advertising, distribution and sale of some of the
Company's products are subject to regulation by one or more governmental
agencies, the most active of which is the Food and Drug Administration ("FDA"),
which regulates those products under the Federal Food, Drug, and Cosmetic Act
("FDCA") and regulations promulgated there under. These products are also
subject to regulation by the Federal Trade Commission ("FTC"), the Consumer
Product Safety Commission ("CPSC"), the United States Department of Agriculture
("USDA") and the Environmental Protection Agency ("EPA"). The Company's
activities are also regulated by various agencies of the states, localities and
foreign countries to which the Company distributes its products and in which the
Company's products are sold. The FDCA has been amended several times, including
by the Nutrition Labeling and Education Act of 1990 ("NLEA") and the Dietary
Supplement Health and Education Act of 1994 ("DSHEA"). The NLEA established a
requirement for the nutrition labeling of most foods including dietary
supplements. The DSHEA introduced a new statutory framework governing the
composition and labeling of dietary supplements.

The DSHEA provides a regulatory framework to ensure safe, quality, dietary
supplements and to foster the dissemination of accurate information about such
products. The DSHEA provides, in the Company's judgment, certain regulatory
benefits for the nutritional supplement industry. Products defined as dietary
supplements under the DSHEA are regulated similarly to food; so much of the
special regulatory clearance is eliminated. In addition, claims about how a
supplement affects the structure or function of the body may be made (although
any statement made must also state that the product is not intended to diagnose,
treat, cure or prevent any disease). Under DSHEA, the FDA is generally
prohibited from regulating the active ingredients in dietary supplements as food
additives or drugs unless product claims are made that a product may diagnose,
mitigate, treat, cure or prevent an illness, disease or malady, in which event
the FDA may attach drug status to a product. An FDA Rule effective February 7,
2001 defines the types of statements that can be made concerning the effect of a
dietary supplement on the structure or function of the body pursuant to DSHEA.
The Rule establishes criteria for determining when a statement is a claim to
diagnose, cure, mitigate, treat or prevent disease thereby making the product an
unapproved new drug. That Rule has not had any material effect on the Company's
existing products and the Company will comply with the provisions of the Rule
for any new products.

As part of its regulatory authority, the FDA may periodically conduct
audits of the physical facilities, machinery, processes and procedures that the
Company uses to manufacture products. The FDA may perform these audits at any
time without advance notice. As a result of these audits, the FDA may order the
Company to make certain changes in its manufacturing facilities and processes.
The Company may be required to make additional expenditures to comply with these
orders or possibly discontinue selling certain products until it complies with
these orders. As a result, the Company's business could be adversely affected.

In February 1997, the FDA issued a Proposed Rule entitled, "CGMP in
Manufacturing, Packing, or Holding Dietary Supplements," which proposes current,
good manufacturing practices (i.e., "CGMPs") specific to dietary supplements and
dietary supplement ingredients. This Proposed Rule, if finalized, would have
required some of the quality control provisions contained in the CGMPs for
drugs. On March 13, 2003, the FDA published a proposed rule in the Federal
Register which proposes comprehensive CGMPs for the manufacturing, packing and
holding of dietary supplements, to help reduce risks seen by the FDA that are
associated with adulterated or misbranded dietary supplement products. The FDA
accepted public comments on the proposed CGMPs until August 11, 2003; but the
FDA has not promulgated final CGMPs. The minimum standards include requirements
for the design and construction of physical plants that are intended to
facilitate maintenance, cleaning, and proper manufacturing operations, for
quality control procedures, for testing final product or incoming and in-process
materials, for handling consumer complaints, and for maintaining records.

On November 18, 1998, the FTC issued its "Dietary Supplements: An
Advertising Guide for Industry." Such guide provides an application of FTC law
to dietary supplement advertising and includes examples of how principles of
advertisement interpretation and substantiation apply in the context of dietary
supplement advertising. The Guide provides additional explanation but does not
substantively change the FTC's existing policy that all supplement marketers
have an obligation to ensure that claims are presented truthfully and to verify
the adequacy of the support behind such claims.

                                     Page 3
<PAGE>

The FTC, which exercises jurisdiction over the advertising of nutritional
and dietary supplements under the Federal Trade Commission Act, has in the past
several years instituted enforcement actions against several nutritional
supplement companies alleging false and misleading advertising of certain
products. These enforcement actions have resulted in the payment of fines and/or
consent decrees by certain of the companies involved. The FTC continues to
monitor advertising with respect to nutritional and dietary supplements. The
Company has not been the subject of any FTC inquiries or actions.

Research and Development Expenses. The Company has not expended a material
amount of its resources on research and development activities.

Costs and Expenses of Compliance with Environmental Laws. The Company does
not have any material amount of cost related to environmental regulations and
the Company does not expect to incur material expenses for that purpose in
fiscal year 2005.

Number of Employees. The approximate number of employees working for the
Company as of the end of fiscal year 2004 was 153.

Item 2. Description of Property.

The Company's headquarters are located in an office-warehouse building of
approximately 88,000 square feet located in Parker, Colorado, which the Company
leases from an affiliate of the Company's President. The property includes the
executive offices of the Company, as well as the Company's manufacturing and
warehouse facilities. The Company's lease expires in September 30, 2006, and the
Company believes that its rental rate is comparable to that which would be
charged by an unaffiliated landlord. (See "Certain Relationships and Related
Transactions")

Item 3. Legal Proceedings.

OraLabs, Inc. is a party to a legal proceeding that was brought in the
Circuit Court of the First Judicial District of Heinz County, Mississippi that
was served on the Company on February 26, 2004. The litigation was brought by
individuals who allege that a five-year-old child ingested a portion of a bottle
that allegedly was manufactured by OraLabs, Inc. for one of its products. The
product was not specified in the complaint. The complaint alleges that the minor
child suffered permanent injuries and damages as a result of the ingestion of
the portion of the bottle, and the plaintiffs claim compensatory damages in an
unstated amount and punitive damages in the amount of $1,925,000. OraLabs,
Inc.'s insurance company is tendering a defense. Punitive damages, however, are
not covered by the insurance policy. OraLabs, Inc. intends to vigorously defend
the suit and believes that it has no liability to the plaintiffs. OraLabs
further believes that even if liability is assessed against it, any compensatory
damages assessed will be covered by its insurance policy. The Company believes
that the possibility of any award of punitive damages against it is very remote.
However, if a significant uninsured judgment is awarded against OraLabs, Inc.,
it could put an extreme financial strain upon it.

The litigation commenced by OraLabs, Inc. against Molded Container Corp.
dba The Humphrey Line, previously disclosed by the Company, was amicably
resolved by a settlement agreement entered into by the parties. The claims of
the parties against each other were dismissed without prejudice and the
dismissal will automatically convert to a dismissal with prejudice upon
compliance with certain matters described in the settlement agreement. As part
of the settlement, OraLabs gave Molded Container Corporation a non-exclusive
license under the OraLabs' patents that were a subject of the litigation.



Item 4. Submission of Matters to a Vote of Security Holders.

No matter was submitted to a vote of security holders during the fourth
quarter of fiscal year 2004.


                                     Page 4
<PAGE>

                                     PART II

Item 5. Market for Common Equity and Related Stockholder Matters.

(a) (i) Market Price of and Dividends on the Company's Common Stock. The
common stock of the Company trades on the NASDAQ Small Cap Market under the
symbol OLAB. The following sets forth the range of high and low bid information
for the Company's common stock for fiscal years 2003 and 2004. The source of
such information is as reported by NASDAQ. All of the following prices and
numbers of shares have been adjusted to give effect to the one-for-two reverse
stock split adopted by the Company on December 16, 2003.




                                      Reported High Bid        Reported Low Bid
                                      -----------------        ----------------
First quarter, fiscal 2003                  $1.76                   $1.16
Second quarter, fiscal 2003                 $1.56                   $1.04
Third quarter, fiscal 2003                  $1.98                   $1.06
Fourth quarter, fiscal 2003                 $1.96                   $1.50
First quarter, fiscal 2004                  $2.80                   $1.50
Second quarter, fiscal 2004                 $2.28                   $1.47
Third quarter, fiscal 2004                  $2.03                   $1.36
Fourth quarter, fiscal 2004                 $5.20                   $1.03




The quotations reflect inter-dealer prices, without adjustment for retail
mark-up, markdown or commission and may not necessarily present actual
transactions.

(ii) Disclosure of Equity Compensation Plans. The Company maintains the
1997 Stock Plan (the "ISOP Plan"), pursuant to which the Company granted 250,000
stock options to employees in 1997. The Company also maintains the 1997
Non-Employee Directors' Option Plan ("Director Plan") under which the Company
makes an initial grant of 10,000 options and annual grants thereafter of 2,500
options to its non-employee directors, subject to the provisions of the plan.



                 Number of securities   Weighted-average    Number of securities
                  to be issued upon     exercise price of    remaining available
Plan Category        exercise of           outstanding       for future issuance
                     outstanding        options, warrants        under equity
                  options, warrants       and rights ($)      compensation plans
                    and rights (#)
                 --------------------  -------------------  --------------------
Equity
compensation           105,400               $2.00                144,600
plans approved
by shareholders

Equity
compensation
plans not              42,500                $2.97                 57,500
approved by
shareholders

Total                  147,900               $2.15                202,100



(b)  As of April 4, 2005, there were approximately 879 record holders of the
     common stock of the Company.

(c)  The Company has not paid any cash dividends and it is not intended that any
     cash dividends will be paid in the foreseeable future.

                                     Page 5
<PAGE>

Item 6. Management's Discussion and Analysis or Plan of Operation.

Critical Accounting Policies

We have identified the policies below as critical to our business
operations and the understanding of our results of operations. The impact and
any associated risks related to these policies on our business operations is
discussed throughout Management's Discussion and Analysis of Financial Condition
and Results of Operations where such policies affect our reported and expected
financial results.

In the ordinary course of business, we have made a number of estimates and
assumptions relating to the reporting of results of operations and financial
condition in the preparation of our financial statements in conformity with
accounting principles generally accepted in the United States of America. Actual
results could differ significantly from these estimates under different
assumptions and conditions. We believe that the following discussion addresses
our most critical accounting policies, which are those that are most important
to the portrayal of our financial condition and results of operations and
require our most difficult, subjective, and complex judgments, often as a result
of the need to make estimates about the effect of matters that are inherently
uncertain.

Allowance for Doubtful Accounts

Although the Company believes that it has strict credit policies, it is not
unusual, in the normal course of business, for a customer to file for bankruptcy
or not pay for product purchased from the Company. The Company has estimated an
allowance based upon current balances and historical information which is
considered an operating expense. This estimate is subject to judgment and could
vary based on the customer mix in the future.

Allowance for Returns

Product is returned by customers for various reasons and the Company has
estimated an allowance based upon the historical rates of these returns. The
sales are recorded net of this allowance. This estimate is subject to judgment
as the historical mix of products sold could vary from the future mix of
products sold. In addition, the customer mix may change in the future.

Inventory Obsolescence

As product mix shifts, the Company must identify any slow-moving and
obsolete inventory it may have on hand. This inventory is reduced to its net
realizable value based upon recent sales and similar transactions occurring in
the open market. This inventory value is an estimate that is subject to changes
in the open market such as demand and availability of product.

Results of Operations. For the period ending December 31, 2004 as compared
with the period ending December 31, 2003.

Product sales decreased $937,641. Please refer to the Trends section for a
detailed explanation.

Cost of goods sold decreased by $281,921. As a percentage of sales, gross
profit was 29.1% in 2004, a decrease of 2.7% from 2003. An increase in overhead
of $436,883 related to the new facility, an increase of freight costs of
$162,133, and an increase in labor of $135,000 were offset by a decrease in raw
materials costs of $1,025,433. The Company anticipates some efficiencies in
manufacturing due to improvements in automation and reduced labor costs in 2005.

Engineering increased $68,841 or 27 %. The increase is due to an increase
in costs related in large part to automation modifications for compatibility
with the new facility. The Company anticipates slightly lower costs in year 2005
to that of year 2004.

Selling and marketing decreased $182,714 or 12%. Sales salaries increased
by $35,000 due to headcount addition. The Company expects sales compensation to
remain the same as a percentage of sales. Advertising increased by $74,000 as
the Company began advertising in trade publications to promote a new segment of
the business. The Company plans to continue this approach. These increases were
offset by a decrease in bad debt expense. A portion of bad debts in year 2003,
in the amount of approximately $230,000, was related to receivables written off
in conjunction with the acquisition of assets.

                                     Page 6
<PAGE>

General and administrative expenses increased $470,372 or 18%. An increase
in salaries and related taxes and benefits of approximately $323,000 was largely
due to additional staffing. The Company anticipates a modest increase in
salaries in year 2005. Legal fees increased approximately $203,000 due in large
part to fees involving litigation issues and other corporate legal services. The
Company will have high legal fees in 2005 relating to the Definitive Agreement
discussed below in "Trends". Moving expenses decreased by $115,000 in 2004.

Other operating expenses decreased by $316,362, or 91%, which was primarily
due to approximately $308,000 loss on abandonment of leasehold improvements to
the two Englewood, CO facilities in 2003, one of which was vacated in 2003 and
the other vacated in February, 2004.

Interest and other income decreased $43,091. The decrease was due to state
income tax credits of approximately $108,000 received in year 2003 related to
prior periods. This was offset by a $87,000 increase in royalty income, and a
decrease in interest income of $22,596. The Company anticipates Interest and
other income will be significantly less in 2004 as royalty income and interest
income will decrease.

Other expenses decreased by $40,634 as approximately $69,000 was for costs
related to manufacturing, distribution and marketing in a foreign country in
2003. The Company does not anticipate significant Other expenses in year 2005,
but cannot guarantee against any unforeseen extraordinary events.

The Company had an after tax loss of $565,108 in 2004 compared to income of
$1,222 for 2003. The effective tax rate decreased from 101% to 32%. For the year
ended December 31, 2003, the Company recognized a tax benefit related to the
completion of the Company's previous year's tax return and recognized the impact
of previous tax credits related to enterprise zone credits and foreign
territorial income exclusions not previously reflected. The change in the
estimate of these credits and exclusions resulted in a one time effective tax
rate of 101%.

Liquidity and Capital Resources.

At December 31, 2004, the Company had $866,432 of cash and a current ratio
of approximately 4 to 1. The Company believes its current capital resources are
sufficient to fund operations for the next twelve months.

Net cash used in operating activities was $653,318 consisting of the
following items:

Accounts Receivable, net of Allowance for doubtful accounts, decreased
$620,852. Receivables decreased $691,096 due to increased collections and
write-offs of uncollectible accounts, while allowances were decreased $70,244.
The Company believes there are adequate allowances given improved collection
efforts as well as improved controls over customer credit approval. (See,
"Allowance for Doubtful Accounts" above).

Inventory increased $456,601 as the Company carried approximately $273,917
more of work in process; approximately $107,626 more in cost of overhead due in
large part to expanded facilities; and approximately $114,209 for cost of labor
allocated to inventory. The Company anticipates inventory levels to remain
similar to year-end numbers.

Income tax receivable increased $86,660 due to $194,168 of current year
loss carried back against taxable income offset by other refunds received and
receivable.

Deferred tax liability and asset increased $303,772; deferred tax liability
long-term increased $14,915; deferred tax asset long-term increased $101,862;
and deferred tax asset - current decreased $216,825. This is attributed to
timing differences in the treatment of deductions for book verses tax income and
net operating losses that will be carried forward and taken against future
taxable income.

Prepaid expenses and deposits increased $161,866 substantially as the
result of a larger deposit on production materials being produced abroad
specifically for the Company by a third party manufacturer, as well as a prepaid
expense for payment and implementation of the companies new software. The
Company anticipates a drop in Prepaid expenses in 2005 when the software
implementation is capitalized.

Accounts payable decreased $195,109. This is due to more timely payment of
invoices as well as an improvement in raw material planning and purchasing
procedures eliminating excess inventory.

Reserve for returns decreased $34,077 consistent with the decrease in sales
from 2003 to 2004. The reserve for returns is calculated as a percentage of
sales with a consideration of historical returns. As sales were flat, and the
additional reserve notwithstanding, the reserve remained the same. Should the
Company experience growth in sales during year 2005 then this reserve will grow
proportionately. (See, "Allowance for Returns" above).

Net cash used in investing activities was $1,194,484 consisting of
investments in property and equipment of $1,191,079. During 2004, the Company
invested in many capital projects to increase automation in the plant.

                                     Page 7
<PAGE>

Trends. The lip balm category, which was approximately 80% of revenues in
both years 2004 and 2003, decreased in 2004. Revenues in 2004 were $10,569,614
as compared to $11,274,552 in year 2003, a 6% decrease. Collectively the volume
of units sold and customer base decreased in 2004 primarily as the result of two
major customers buying at a significantly reduced level. We expect 2005 to be in
the range of 2004 with these customers. In 2005, the Company will, through its
normal sales process, attempt to increase its lip balm business, however, there
are no assurances that any increase will happen. The Company hopes to implement
some cost cutting strategies to reduce its operating cost and to increase its
gross margins. This includes product line trimming and a narrower focus on what
the Company sells.

The sour drops and breath fresheners revenues were $2,166,262 in year 2004
compared to $2,211,111 in year 2003, or a 2% decrease. The decrease is not
significant and sales should remain stable through 2005.

The nutritional supplement revenues, on a relatively smaller scale, were
down to $414,594 in 2004 as compared to $582,557 in 2003, or a 29% decrease. The
Company has been unable to develop additional customers for these products.
Therefore, the Company anticipates these revenues will stay substantially the
same.

The international business revenues were $918,104 in 2004 as compared to
$870,175 in 2003, a 6% increase. This compares favorably to the 30% decrease in
2003. Although this business represents less than 10% of the Company's revenues
it is still considered important to the overall success of the Company. Sales to
certain countries significantly decreased in 2004, but were favorably offset by
a spread of increased sales in numerous others. In 2004, the Company abandoned
its manufacturing plans in South America. In 2005, the Company anticipates
continued sales to its major international customers with hopes of expanding its
distribution to new markets.


The following table shows aggregated information about contractual
obligations as of December 31, 2004:
<TABLE>
<CAPTION>

                                                                       Payments Due by Period

                                    --------------------------------------------------------------------------------------------
                                    Total            Less Than 1 Year           1-3 Years        4-5 Years         After 5 Years
--------------------------------------------------------------------------------------------------------------------------------
<S>                               <C>                          <C>                <C>
Long-Term Debt                    $24,656                      $12,581            $12,075

Building Lease                   $780,000                     $445,000           $335,000

Vehicle Lease                      $6,000                       $6,000

--------------------------------------------------------------------------------------------------------------------------------
Total                            $810,656                     $463,581          $347,075

================================================================================================================================
</TABLE>


Other than the above, OraLabs does not know of any other demands,
commitments, uncertainties, or trends that will result in or that are reasonably
likely to result in its liquidity increasing or decreasing in any material way.



Impact of Inflation. The Company's financial condition has not been
affected by the modest inflation of the recent past. The Company believes that
revenues will not be materially affected by inflation. The Company's lip care
and oral care products are primarily very low retail price points and impulse
items. The nutritional supplements are a small part (approximately 3%) of
revenues in a category that is on a downward trend and could be negatively
impacted by inflation.

As previously announced by the Company in its Form 8-K filed on February
23, 2005, OraLabs entered into a Definitive Agreement with NVC Lighting
Investment Holdings Limited under which OraLabs will acquire NVC and convey its
ownership of OraLabs, Inc. to OraLabs' President, Gary H. Schlatter. Control of
the Company would change from Mr. Schlatter to the owners of NVC. Closing under
the Definitive Agreement is conditioned upon many requirements and there can be
no assurance that the closing will occur. If the parties do not otherwise
terminate the Definitive Agreement, then OraLabs, in anticipation of a meeting
of its shareholders called to approve the transactions, will file with the
Securities and Exchange Commission a Proxy Statement that will include more
detailed information about the Definitive Agreement and the proposed
transactions.

CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS:

The provisions of the Private Securities Litigation Reform Act of 1995 (the
"Reform Act") provide companies with a "safe harbor" when making forward-looking
statements. This "safe harbor" encourages companies to provide prospective
information about their companies without fear of litigation. The Company wishes
to take advantage of this "safe harbor" and is including this section in its
Annual Report on Form 10-KSB in order to do so. All statements in this Form
10-KSB that are not historical facts, including without limitation statements
about management's expectations for any period beyond the fiscal year ended
December 31, 2004, are forward-looking statements and involve various risks and
uncertainties, many of which are beyond the control of the Company, and any one
of which, or a combination of which, could materially reflect the results of the
Company's operations and whether forward-looking statements made by the Company
ultimately prove to be accurate.

The following discussion outlines certain risk factors that in the future
could affect the Company's results and cause them to differ materially from
those that may be set forth in any forward-looking statement made by or on
behalf of the Company. The Company cautions the reader, however, that this list
of risk factors and others discussed elsewhere in this report may not be
exhaustive.

                                     Page 8
<PAGE>

NASDAQ Listing. Although the Company believes that it has been in
compliance with requirements for continued listing since it enacted a 1 for 2
reverse stock split in December, 2003, the Company can give no assurance that it
will continue to meet the requirements for continued listing of its common stock
on the NASDAQ SmallCap Market.

Competition. The businesses in which the Company is engaged are highly
competitive and are engaged in to a large extent by companies which are
substantially larger and have significantly greater resources than the Company.
Although the Company believes that its branded products have achieved some
measure of name recognition, to a large extent the Company does not have the
capital resources, marketing and distribution networks, manufacturing
facilities, personnel, product name recognition or advertising budget of the
larger companies. If the Company were to be forced out of the large mass
retailers by larger, better financed competitors, it would be reliant on smaller
niche markets that the larger, better financed competitors are not interested
in. The same situation applies to international business, where there are larger
more dominant competitors that the Company must always deal with. The industries
in which the Company competes in experience consolidations of competitors from
time to time and the Company's business could be adversely affected by such
activities. There can be no assurance that the Company will be able to compete
successfully in the future. To respond to competition the Company created added
value packaging for promotions that resulted in increased cost of goods sold.
There is an increased effort by all competitors for shelf and counter space and
the cost of product placement is increasing. There is no assurance that the
Company will be able to maintain its shelf and counter presence in the future.

Managing Manufacturing Requirements. The Company has done several things to
position itself for stability in 2005, which the Company hopes will help it
return to profitability. In positioning for stability and profitability, the
Company has made changes to management, customer service, manufacturing, and
sales and administrative personnel. These changes have come at costs that have
put the Company in an unprofitable position for 2004. The Company has been in
its new facility since February of 2004. The extra space has helped to allow the
company to more efficiently process its orders. However the associated costs
with the new facility have not yet been offset by increased sales or
efficiencies. The Company plans to reduce its product offerings in order that it
will be able to lower its cost to produce fewer product offerings. The Company
hopes to be able to return to a state of profitability. However there are no
assurances that it will. The added overhead from the new facility was a partial
contributor to the loss in 2004.

The Company experienced a period of significant growth during fiscal years
ended December 31, 1996 and 1997. Significant growth did not occur in fiscal
year 1998, but it occurred again in 1999, 2000, 2001. The Company did not
experience growth in 2002, 2003 or 2004. The volume of manufacturing has been
similar for the past four years. The Company has had opportunities to grow its
business but has not done so, in part, because of capacity issues in
manufacturing. In addition, the loss of a significant number of customers, or a
significant reduction in purchase volume by or financial difficulty of such
customers, for any reason, could have a material adverse effect on the Company.
Successful management of growth, if it occurs, will require the Company to
improve its financial controls, operating procedures and management information
systems, and to train, motivate and manage its employees.

Product Liability Insurance. Because the Company manufactures and sells
certain products designed to be ingested, it faces the risk that materials used
for the final products may be contaminated with substances that may cause
sickness or other injury to persons who have used the products. Although the
Company maintains standards designed to prevent such events, certain portions of
the process of product development, including the production, harvesting,
storage and transportation of raw materials, along with the handling,
transportation and storage of finished products delivered to consumers, are not
within the control of the Company. Furthermore, sickness or injury to persons
may occur if products manufactured by the Company are ingested in dosages which
exceed the dosage recommended on the product label or are otherwise misused. The
Company cannot control misuse of its products by consumers or the marketing,
distribution and resale of its products by its customers. With respect to
product liability claims in the United States, the Company has $2 million per
occurrence and $2 million in aggregate liability insurance. However, there can
be no assurance that such insurance will continue to be available, or if
available, will be adequate to cover potential liabilities. The Company
generally does not obtain contractual indemnification from parties supplying raw
materials or marketing its products and, in any event, any such indemnification
is limited by its terms and, as a practical matter, to the creditworthiness of
the indemnifying party.

                                     Page 9
<PAGE>

Dependence on Key Personnel. The Company's future success depends in large
part on the continued service of its key personnel. In particular, the loss of
the services of Gary Schlatter, its President and Chief Executive Officer, could
have a material adverse effect on the operations of the Company. The Company's
subsidiary has an employment agreement with Mr. Schlatter which expires on April
30, 2006, but it is expected to be extended. The Company's future success and
growth also depends on its ability to continue to attract, motivate and retain
highly qualified employees. There can be no assurance that the Company will be
able to do so.

Government Regulation. The manufacturing, processing, formulation,
packaging, labeling and advertising of some of the Company's products are
subject to regulation by one or more federal agencies and under various laws
(see Description of Business-Government Regulation above). There can be no
assurance that the scope of such regulations will not change or otherwise cause
an increase in the expenses and resources of the Company which must be applied
to complying with such regulations. As an example, the Company's sun-block lip
balms are regulated by the FDA. If the FDA were to conclude that any of the
Company's products violate FDA rules or regulations, the FDA may seek to
restrict or remove such products from the market. Such action may be taken
against the Company and any entity which manufactures products for the Company.
As an additional example, regulations concerning good manufacturing practices
with respect to OTC drugs and nutritional supplements do have an adverse impact
upon the cost or methods of producing the products. It is anticipated that new
labeling laws currently pending will result in increased costs, in order to be
in compliance .

The Company's business is also regulated by various agencies of the states
and localities in which the Company's products are sold and governmental
regulations in foreign countries where the Company sells or may seek to commence
sales. Such regulations could prevent or delay entry into a market or prevent or
delay the introduction of Company products. For example, international sales are
expected to be slowed by the long process of registering new products.

The Company may be subject to additional laws or regulations administered
by the FDA or other federal, state or foreign regulatory authorities, the repeal
or amendment of laws or regulations or more stringent interpretations of current
laws or regulations, from time to time in the future. The Company is unable to
predict the nature of such future laws, regulations, interpretations or
applications, nor can it predict what effect additional governmental regulations
or administrative orders, when and if promulgated, would have on its business in
the future. They could, however: require reformulation of certain products to
meet new standards; recall or discontinue certain products not able to be
reformulated; impose additional record keeping requirements; expanded
documentation of the properties of certain products; or expand or differentiate
labeling and scientific substantiation regarding ingredients, product claims,
safety or efficacy. Failure to comply with applicable FDA requirements could
result in sanctions being imposed on the Company or the manufacturers of its
products, including, warning letters, fines, product recalls and seizures. Any
or all such requirements could have a material adverse effect on the Company's
results of operations and financial condition.

Dependence upon Significant Distributors and Retailers. The Company had two
major customers that accounted for approximately $1,950,000 and $1,400,000
respectively, or 15% and 11% of net sales during the year ended December 31,
2004. The Company had over 1,000 purchasing customers in fiscal 2004 and
believes that the loss of revenues from any customer could gradually be
replaced, but there could be adverse effects upon the Company's business until
those revenues are replaced. The Company is always at risk for its customers
filing for bankruptcy or liquidation. This has happened in the past and could
happen again in the future.

Dependence upon Third Party Suppliers. With respect to some of the
Company's products, the product itself is formulated and supplied to the Company
by third party vendors, and the Company then packages the products for sale. For
other products, the Company provides some or all of the raw materials and a
third party completes preparation of the product and/or its packaging. Should
these relationships terminate, or should these parties be otherwise unable to
perform their obligations on terms satisfactory to the Company, the Company
would be required to establish relationships with substitute parties. Although
the Company believes that it can do so and that raw materials are available at
comparable prices from several suppliers, there can be no assurance that this
will be the case, in which case there could be a material adverse effect upon
the Company.

                                     Page 10
<PAGE>

No Assurance of Proprietary Protection. The Company owns numerous patents.
The Company also holds several domestic and international trademarks and has
several applications pending. Certain aspects of the Company's business,
although not the subject of patents, include formulations and processes
considered to be proprietary in nature. There can be no assurance that any such
"proprietary" information will not be appropriated or that the Company's
competitors will not independently develop products that are substantially
equivalent or superior to the Company's. Even if the pending trademark
registrations are issued to the Company, there can be no assurance that the
Company would be able to successfully defend its patents or trademarks against
claims from or use by competitors, and there can be no assurance that the
Company will be able to obtain patent or trademark protection for any new
products. In addition, in the event that any of the Company's products are
determined to infringe upon the patents or proprietary rights of others, the
Company could be required to modify its products or obtain licenses for the
manufacture or sale of the products, or could be prohibited from selling the
products.

No Assurance of Scientific Proof. The Company's nutritional supplement
products are intended to provide relief of certain symptoms or to otherwise aid
in the health of the consumers. If scientific data were to conclude that the
products do not do so, or if for any other reason the Company's products were
not viewed by the public as providing any meaningful benefit, there could be an
adverse effect upon the sales of the products. In addition, the nutritional
supplement industry has been known to experience radical ups and downs of
certain product sales in a short period of time which could adversely affect the
Company's sales or inventory positions. Sometimes these cycles are the result of
studies or the media creating a positive or negative impact on the industry and
the public at large.

Limited Distribution for Nutritional Supplement Products. The Company began
selling its nutritional supplement products in 1998. The nutritional supplement
industry is influenced by products that become popular due to changing consumer
tastes and media attention. The Company is competing against much larger and
better established manufacturers in this business than in the Company's primary
business. The Company does not expect its sales of nutritional products to
significantly change.

Item 7. Financial Statements.

Financial Statements meeting the requirements specified in Item 7 of Form
10-KSB follow the signature page and are listed in Item 13 of this Annual Report
on Form 10-KSB.

Item 8. Changes In and Disagreements with Accountants on Accounting and
Financial Disclosure. None.


Item 8A. Controls and Procedures. Control deficiencies have been identified
by management in consultation with Ehrhardt Keefe Steiner & Hottman PC, the
Company's independent auditors. Certain matters involving internal control
deficiencies considered to be a material weakness and reportable conditions
under standards established by the American Institute of Certified Public
Accountants have been reported to the audit committee of the board of directors.
The material weakness relates to adjustments made by the auditors in order for
inventory to be properly stated. The reportable conditions include conditions
surrounding the following: financial reporting and lack of oversight over the
accounting processes. The Company has hired a CPA with experience in the
manufacturing industry and implemented a widely used, mid-sized business
accounting and inventory system to address its control deficiencies. The
benefits of implementation of the new software along with training staff on the
Company's new systems had not been fully realized at the end of 2004. As a
result some of the Companies reportable conditions were still present at the end
of 2004. Management believes that the aforementioned reportable conditions will
be corrected during 2005.

Evaluation of Disclosure Controls and Procedures. The Company's Chief
Executive Officer and its Chief Financial Officer, after evaluating the
effectiveness of the Company's disclosure controls and procedures (as defined in
the Securities Exchange Act of 1934 Rules 13a-14(c) and 15d-14(c) as of a date
within 90 days of the filing date of this annual report on Form 10-KSB (the
"Evaluation Date")), have concluded that as of the Evaluation Date, and except
as provided above, the Company's disclosure controls and procedures were
adequate and effective to ensure that material information relating to the
Company and its consolidated subsidiaries would be made known to them by others
within those entities, particularly during the period in which this annual
report on Form 10-KSB was being prepared.

Our external auditors have not issued an attestation report on management's
assessment of the Company's internal control over financial reporting, as it is
not required for the Company at this time.

                                     Page 11
<PAGE>

                                    PART III

Item 9. Directors, Executive Officers, Promoters and Control Persons;
Compliance with Section 16(a) of the Exchange Act

The following table identifies each of the Company's directors and
executive officers:

<TABLE>
<CAPTION>
                                                                                              Year First
                                                                                              Elected to
                                                                                               Board of
               Name                     Age           Positions with the Company               Directors
               ----                     ---           --------------------------               ---------

<S>                      <C>           <C>                                                       <C>
        Gary H. Schlatter(2)............48        Chief Executive Officer, President,            1997
                                                  Treasurer, Director
        Allen R. Goldstone..............52        Director                                       1997

        Michael I. Friess...............55        Director(1), Secretary                         1997

        Robert C. Gust..................48        Director(1)                                    2000

        Emile J. Jordan.................46        Chief Financial Officer

__________________
</TABLE>

(1)      Audit Committee member

(2)      See "Certain Relationships and Related Transactions" below.

     Mr. Schlatter and Mr. Goldstone were elected to their positions in May 1997
upon consummation of the transaction by which the Company's subsidiary, OraLabs,
Inc., was acquired by SSI Capital Corp. (the Company's predecessor). Mr. Friess
was appointed as a Director on September 8, 1997 and Mr. Gust was elected as a
director on May 26, 2000. All directors serve as such until their successors are
elected and qualified. No family relationship exists among the Directors or
between any of such persons and the Executive Officers of the Company. Mr.
Goldstone resigned from the Board on August 24, 1999 and was reappointed to the
Board on December 30, 1999.

     Gary H. Schlatter is the founder (in 1990) of the Company's subsidiary,
OraLabs, Inc., and has served as the President, Chief Executive Officer,
Treasurer and Secretary of the subsidiary since that time. He also serves in the
positions listed in the above table with respect to the Company. Mr. Schlatter
holds his offices (other than the position of director) pursuant to an
employment agreement (see, "Executive Compensation").

     Michael Friess is a self-employed attorney licensed to practice law in the
State of Colorado. He was a partner from January 1983 to December 1993 in the
New York City law firm of Schulte, Roth & Zabel, where his practice emphasized
taxation.

     Allen R. Goldstone is the managing member of Creative Business, LLC, a
company that is engaged in business consultation, and he has held that position
since 1998 (and prior thereto he was and still serves as president of Creative
Business Strategies, Inc., another business consulting firm). Mr. Goldstone has
also served as a management consultant since 1988. For calendar year 1997, Mr.
Goldstone was an employee of the Company's subsidiary, in which capacity he was
in charge of investor relations.

     Robert C. Gust is the co-founder (January 2002) and Partner of Apogee
Group, a business brokerage and consulting firm. From April 1997 to December
2001, Mr. Gust was co-founder and Senior Vice-President of Business Development
for Protocol Communications, Inc., a Massachusetts company engaged in the
business of owning and operating integrated marketing services companies. From
June 1993 until the formation of Protocol Communications, Inc., Mr. Gust was
Vice-President of Sales (North America) for Indigo America.

     Emile J. Jordan has served as the Comptroller of the Company since May
1997. He has served as Comptroller of the subsidiary, OraLabs, Inc. on a full
time basis since April 1, 1994. Mr. Jordan is the Chief Financial Officer of the
Company. Mr. Jordan was elected to his position by the Board of Directors of the
Company and holds his office at the discretion of the Board of Directors or
until his earlier death or resignation.

Additional information with respect to the Board of Directors.

The Company has a standing Audit Committee consisting of Michael I. Friess
and Robert C. Gust. The Audit Committee reviews the consolidated financial
statements and independent auditors' report, including recommendations from the
independent auditors regarding internal controls and other matters. The Audit
Committee held one meeting during fiscal year 2004 to discuss the financial
statements to be part of the Company's Form 10-KSB for fiscal year 2003, and
held one meeting with the Company's independent auditors with respect to the
Company's Annual Report on Form 10-KSB for fiscal year 2004. The meetings were
held by telephone conference call.
<PAGE>

The Board of Directors adopted a revised written charter for the Audit
Committee in March 2004, which was attached as Appendix A to the Company's Proxy
Statement filed on April 20, 2004.

During the fiscal year ended December 31, 2004, the Board of Directors did
not meet in person but met three times by telephone conference, and each
Director participated in the meeting. The Board also took action on numerous
occasions without a formal meeting.



Section 16(a) Beneficial Ownership Reporting Compliance.

Section 16(a) of the Securities and Exchange Commission requires our
directors, executive officers and holders of more than 10% of our common stock
to file with the Securities and Exchange Commission reports regarding their
ownership and changes in ownership of our securities. The Company believes that
during fiscal year 2004, its directors, executive officers and 10% owners
complied with all Section 16(a) filing requirements with the following
exceptions: directors Friess, Goldstone and Gust each filed a late report with
respect to options awarded to each of them in June 2004 under the Company's 1997
Non-employee Directors Option Plan.

Code of Ethics. Our Board of Directors adopted a code of ethics that
applies to our Principal Executive Officer, Gary H. Schlatter, and our Principal
Financial Officer, Emile Jordan. Both of these individuals signed an
acknowledgement of his receipt of our code of ethics. We are filing a copy of
our code of ethics with the Securities and Exchange Commission by including it
as Exhibit 14.1 to this report.

Item 10. Executive Compensation.

The following table sets forth information regarding compensation for
services rendered, in all capacities, awarded or paid to or earned by the Chief
Executive Officer of the Company during the last three fiscal years and earned
by Emile Jordan in fiscal year 2004. No other executive officer of the Company
received a total annual salary and bonus in excess of $100,000 during any of the
last three fiscal years.
<TABLE>
<CAPTION>

                                             Summary Compensation Table

                                           Annual Compensation                         Long Term Compensation
                                           -------------------                         ----------------------
       Name and                                                                              Shares Under-
  Principal Position       Year     Salary ($)     Bonuses ($)      Other ($)     Other     lying Options
  ------------------       ----     ----------     -----------      ---------     -----     -------------

<S>                        <C>      <C>                 <C>         <C>             <C>        <C>
Gary H. Schlatter, CEO     2004     393,105(1)          0           22,699(3)       0          30,500(1)
                           2003     370,346(1)          0           22,339(3)       0          30,500(1)
                           2002     335,468(1)          0           27,009(2)       0          30,500(1)

Emile Jordan, CFO          2004     109,400             0                0          0          25,500
</TABLE>



1    Includes 30,500 shares underlying 30,500 options granted in the fiscal year
     ended December 31, 1997 to Mr. Schlatter's spouse, an employee of the
     Company, under the Company's 1997 Stock Plan and a $10,000 annual salary to
     the spouse. Beneficial ownership of such securities and spouse's salary is
     disclaimed by Mr. Schlatter.

2    Includes expenses for automobiles and related insurance and other
     automobile expenses, as well as payments made to a company owned by Mr.
     Schlatter for computer equipment and furniture.

3    Includes expenses for automobiles and related insurance and other
     automobile expenses.

Standard Compensation Arrangements for Directors

The directors other than Mr. Schlatter are compensated monthly for services
provided as directors. Currently, all three non-employee directors receive
$2,000 monthly as director's fees. The Company may modify those arrangements at
any time. There were no other arrangements pursuant to which any director of the
Company was compensated during the past fiscal year for any service provided as
a director. However, the Company has a Non-Employee Director Stock Option Plan
under which directors who are not employees are granted (at the time of initial
election or appointment to the Board) 10,000 options to purchase common stock
and are thereafter granted 2,500 options annually so long as they continue to
serve as non-employee directors. All of the options are exercisable at the
market price of the common stock at the time of grant and vest proportionately
over a four year period.

Agreements with Executive Officers

The only employment contract between the Company and any executive officer
of the Company who received total salary and bonus during fiscal year 2004 in
excess of $100,000 is an Amended and Restated Employment Agreement with Gary H.
Schlatter. Except for that Agreement as described below, the Company has not
entered into any compensatory arrangement pursuant to which any executive
officer of the Company will receive payment from the Company as a result of the
executive officer's resignation, retirement or termination of employment or as a
result of a change in control of the Company. There is no employment contract
between the Company and Emile J. Jordan.
<PAGE>

Effective May 1, 2003, the Company's subsidiary, OraLabs, Inc., entered
into an Amended and Restated Employment Agreement ("Employment Agreement") with
Gary Schlatter. The Employment Agreement extended the term of Mr. Schlatter's
employment through April 30, 2006, unless terminated earlier pursuant to the
provisions of the Employment Agreement. Under the Employment Agreement, Mr.
Schlatter agrees to devote such time and attention to the business of OraLabs,
Inc. as may be required to fulfill his duties, which is expected to require a
substantial amount of his working time.

Under the Employment Agreement, Mr. Schlatter is paid a base salary of
$392,645 per year for the first twelve (12) months, $431,909 per year for the
next twelve (12) months, and $475,100 for the final twelve (12) months. Bonus
compensation is payable to Mr. Schlatter as may be determined by the Board of
Directors in its discretion. Mr. Schlatter also is paid or reimbursed for lease
and insurance expenses for automobile and cellular telephone expenses. Under the
Employment Agreement, Mr. Schlatter has agreed that during its term and for a
period of one (1) year thereafter, he will not participate in any business
competitive to that of the business of OraLabs, Inc., except with respect to
limited passive investments, and that he will never disclose or utilize any
trade secrets or proprietary information of OraLabs, Inc. except within the
scope of his employment.

Under specified circumstances involving a change in control, Mr. Schlatter
may terminate the Employment Agreement and receive a lump sum payment equal to
all of the compensation to which he otherwise would have been entitled had the
Employment Agreement remained in effect for its entire term.

Item 11. Security Ownership of Certain Beneficial Owners and Management.


     The following table sets forth, as of April 4, 2005, information regarding
the beneficial ownership of Common Stock (i) by each Director,(ii) by each
Executive Officer listed in the Summary Compensation table below, (iii) by all
Directors and current Executive Officers as a group (five persons), and (iv) by
each person or group known by the Company to own beneficially in excess of five
percent (5%) of the Common Stock:
<TABLE>
<CAPTION>

              Name and Address                           Amount and Nature of
           of Beneficial Owner(6)                        Beneficial Ownership           Percent of Class
           ----------------------                        --------------------           ----------------

<S>                                                       <C>             <C>               <C>   <C>
          Gary H. Schlatter                               3,729,350 shares(1)               78.21%(1)
          18685 East Plaza Drive
          Parker, Colorado 80134

          Allen R. Goldstone                               36,250 shares (2)                    *
          5353 Manhattan Circle
          Suite 101
          Boulder, Colorado 80303

          Michael I. Friess                                 8,750 shares (3)                    *
          5353 Manhattan Circle
          Suite 101
          Boulder, Colorado 80303

          Robert C. Gust                                   24,750 shares (4)                    *
          7N551 Cloverfield Circle
          St. Charles, IL 60175

          Emile Jordan
          18685 East Plaza Drive
          Parker, CO 80134                                 25,500 shares (5)                                   *


          All directors and executive                   3,824,600 shares (1), (2), (3), (4),(5) 79.26%
            officers as a group (five persons)

*        Less than one percent

__________________
</TABLE>

(1)  Includes 100,000 shares held by The Schlatter Family Partnership, of which
     Gary H. Schlatter and his spouse are the general partners. Mr. Schlatter's
     spouse may be deemed the beneficial owner of some or all of the shares.
     Does not include 30,500 shares that Mr. Schlatter's spouse, an employee of
     the Company, has the right to acquire on April 4, 2005, or within sixty
     (60) days thereafter, pursuant to outstanding options.
<PAGE>

(2)  Includes 3,750 shares that he has the right to acquire on April 4, 2005, or
     within sixty (60) days thereafter, pursuant to outstanding options.

(3)  Includes 6,250 shares that he has the right to acquire on April 4, 2005 or
     within sixty (60) days thereafter, pursuant to outstanding options.

(4)  Includes 13,750 shares that he has the right to acquire on April 4, 2005 or
     within sixty (60) days thereafter, pursuant to outstanding options.

(5)  Includes 25,500 shares that he has the right to acquire on April 4, 2005 or
     within sixty (60) days thereafter, pursuant to outstanding options(.)

(6)  Unless otherwise noted, the stockholders identified in this table have sole
     voting and investment power. The sole person known to the Company to be the
     beneficial owner of more than five percent (5%) of the class of outstanding
     stock is Gary H. Schlatter, whose address is c/o OraLabs Holding Corp.,
     18685 East Plaza Drive, Parker, Colorado 80134.

Change in Control.

As previously announced by the Company in its Form 8-K filed on February
23, 2005, OraLabs entered into a Definitive Agreement with NVC Lighting
Investment Holdings Limited under which OraLabs will acquire NVC and convey its
ownership of OraLabs, Inc. to OraLabs' President, Gary H. Schlatter. Control of
the Company would change from Mr. Schlatter to the owners of NVC. Closing under
the Definitive Agreement is conditioned upon many requirements and there can be
no assurance that the closing will occur. If the parties do not otherwise
terminate the Definitive Agreement, then OraLabs, in anticipation of a meeting
of its shareholders called to approve the transactions, will file with the
Securities and Exchange Commission a Proxy Statement that will include more
detailed information about the Definitive Agreement and the proposed
transactions.


Item 12. Certain Relationships and Related Transactions.

Gary H. Schlatter, through an affiliated entity, is the owner of the
property leased by OraLabs (the Company's subsidiary) that serves as the
Company's headquarters, manufacturing facility and warehouse facility. The lease
expires on September 30, 2006. Prior to the Company's relocation in 2004, Mr.
Schlatter individually and an affiliated entity respectively leased the two
facilities from which the Company conducted its business. Total rent paid by the
Company for rent of those facilities in 2004 was $83,690. Rent paid to Mr.
Schlatter's affiliated entity in 2004 after the relocation was $446,088. The
Company believes that its rental rate is comparable to that which would be paid
to unaffiliated parties, and the Company believes that if the leases were not to
be renewed, the Company could obtain alternative space.

Item 13. Exhibits and Reports on Form 8-K.

(a) The following documents are filed as a part of this Form 10-KSB immediately
following the signature pages:

1. Consolidated Financial Statements (OraLabs Holding Corp. and Consolidated
Subsidiaries):
                          Independent Auditors' Report
                 Consolidated Balance Sheet - December 31, 2004
               Consolidated Statements of Operations for the years
                  ended December 31, 2004 and December 31, 2003
               Consolidated Statement of Stockholders' Equity from
                   December 31, 2002 through December 31, 2004
               Consolidated Statements of Cash Flows for the years
                        ended December 31, 2004 and 2003
                   Notes to Consolidated Financial Statements

2. Exhibits required to be filed are listed below:

Certain of the following exhibits are hereby incorporated by reference
pursuant to Rule 12(b)-32 as promulgated under the Securities and Exchange Act
of 1934, as amended, from the reports noted below:

Exhibit
  No.                Description
  ---                -----------
3.1(i)(1)    Articles of Incorporation
3.1(ii)(2)   Amended and Restated Bylaws
3.1(ii)(4)   Second Amended and Restated Bylaws
4(2)         Specimen Certificate for Common Stock
<PAGE>

10.1(2)      1997 Stock Plan
10.2(2)      1997 Non-Employee Directors' Option Plan
10.3(3)      Amended and Restated Employment Agreement Between the
             Company's Subsidiary and Gary Schlatter
10.4(2)      Stock Option Grant under 1997 Non-Employee Directors' Option Plan
10.5(i)(5)   Business Lease between the Company's Subsidiary and Gary
             Schlatter (September 1, 2000)
10.5(iii)(8) Amended Business Lease between the Company's Subsidiary
             and 2780 South Raritan, LLC effective October 15, 2000.
10.5(iv)(9)  Lease between the Company's Subsidiary and 18501 East Plaza Drive,
             LLC dated September 4, 2003
10.9(7)      Agreement (effective May 1, 2000, amending the Employment
             Agreement listed above as Exhibit 10.3).
10.10(10)    Amended and Restated Employment Agreement between the
             Company's Subsidiary and Gary Schlatter dated May 1, 2003
10.11(11)    Stock Exchange Agreement between the Company, NVC Lighting
             Investment Holdings Limited and others dated February 23, 2005
11           No statement re: computation of per share earnings is required
             since such earnings computation can be clearly determined from the
             material contained in this Annual Report on Form 10-KSB.
14.1(12)     Code of Ethics
21(2)        List of Subsidiaries of the Company
23.1(12)     Consent of Independent Public Accountants (Ehrhardt Keefe Steiner &
             Hottman P.C.)
31.1(12)     Certification Pursuant To 18 U.S.C. Section 1350, As Adopted
             Pursuant To Section 302 Of The Sarbanes-Oxley Act Of 2002
31.2(12)     Certification Pursuant To 18 U.S.C. Section 1350, As Adopted
             Pursuant To Section 302 Of The Sarbanes-Oxley Act Of 2002
32.1(12)     Certification Pursuant To 18 U.S.C. Section 1350, As Adopted
             Pursuant To Section 906 Of The Sarbanes-Oxley Act Of 2002
32.2(12)     Certification Pursuant To 18 U.S.C. Section 1350, As Adopted
             Pursuant To Section 906 Of The Sarbanes-Oxley Act Of 2002

                                     Page 13

<PAGE>

1 Incorporated herein by reference to Exhibit C of the Definitive Information
Statement filed by the Company's predecessor, SSI Capital Corp., on July 24,
1997.

2 Incorporated herein by reference to the Company's Form 10-K filed for fiscal
year 1997.

3 Incorporated herein by reference to Exhibit B of the Form 8-K filed by the
Company's predecessor, SSI Capital Corp., on May 14, 1997.

4 Incorporated herein by reference to the Company's Form 10-KSB filed for fiscal
year 1998.

5 Incorporated herein by reference to the Company's Form 10-QSB filed for the
quarter ended September 30, 2000.

6 N/A

7 Incorporated herein by reference to the Company's Form 10-QSB filed for the
quarter ended March 31, 2000.

8 Incorporated herein by reference to the Company's Form 10-KSB filed for fiscal
year 2000.

9 Incorporated herein by reference to the Company's Form 10-QSB filed for the
quarter ended September 30, 2003.

10 Incorporated herein by reference to the Company's Form 10-QSB filed for the
quarter ended June 30, 2003.

11 Incorporated herein by reference to the Company's Form 8-K filed February 24,
2005.

12 Filed herewith.

Item 14.  Principal Accountant Fees and Services.

The following table presents fees for professional audit services rendered
by Ehrhardt Keefe Steiner & Hottman P.C. ("EKS&H") for the audit of our annual
financial statements for the years ended December 31, 2004 and December 31,
2003, and the reviews of the financial statements included in each of our
quarterly reports on Form 10-QSB during the fiscal years ended December 31, 2004
and 2003:

                                       2004                                2003
Audit Fees                           $65,500                             $62,000
Audit-Related Fees                      $0                                  $0
Tax Fees                                $0                                  $0
All Other Fees                          $0                                  $0

Audit Fees are fees incurred in connection with the audit of the Company's
consolidated annual financial statements and the review of financial statements
in the Company's quarterly reports on Form 10-QSB. All Other Fees are incurred
for services other than those described above. The Audit Committee will
pre-approve the performance by EKS&H of any services other than those relating
to the audit or review of the Company's financial statements, but no other
services are anticipated at this time.




                                     Page 14
<PAGE>

                                   SIGNATURES

In accordance with Section 13 or 15(d) of the Exchange Act, the Registrant
caused this report to be signed on its behalf by the undersigned, thereunto duly
authorized.

                                                         ORALABS HOLDING CORP.





                                 By:     /s/ Gary H. Schlatter
                                         ---------------------------------------
                                         Gary H. Schlatter, President

                                 By:     /s/ Emile Jordan
                                         ---------------------------------------
                                         Emile Jordan, Chief Financial Officer
Date:    April 29, 2005



In accordance with the Exchange Act, this report has been signed below by
the following persons on behalf of the Registrant and in the capacities and on
the dates indicated.





        Signature                          Title                     Date
        ---------                          -----                     ----

 /s/ Gary H. Schlatter            Director, President,          April 29, 2005
-----------------------------     Chief Executive Officer
     Gary H. Schlatter


 /s/ Michael I. Friess            Director, Secretary           April 29, 2005
-----------------------------
     Michael I. Friess


 /s/ Allen R. Goldstone                  Director               April 29, 2005
-----------------------------
     Allen R. Goldstone


/s/ Robert C. Gust                       Director               April 29, 2005
-----------------------------
    Robert C. Gust



                                     Page 15
<PAGE>

 Consolidated Financial Statements And Independent Auditors' Report December 31,
                                      2004

                     ORALABS HOLDING CORP. AND SUBSIDIARIES

                                Table of Contents



                                                                            Page
                                                                            ----
Report of Independent Registered Public Accounting Firm ......................1

Consolidated Financial Statements

     Consolidated Balance Sheet...............................................2

     Consolidated Statements of Operations....................................3

     Consolidated Statement of Changes in Stockholders' Equity................4

     Consolidated Statements of Cash Flows....................................5

Notes to Consolidated Financial Statements.................................6-14



             REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

To the Board of Directors and Stockholders
OraLabs Holding Corp.
Parker, Colorado

We have audited the consolidated balance sheet of OraLabs Holding Corp. and
Subsidiaries as of December 31, 2004 and the consolidated statements of
operations, changes in stockholders' equity and cash flows for the years ended
December 31, 2004 and 2003. These consolidated financial statements are the
responsibility of the Company's management. Our responsibility is to express an
opinion on these consolidated financial statements based on our audits.

We conducted our audits in accordance with standards of the Public Company
Accounting Oversight Board (United States). Those standards require that we plan
and perform the audit to obtain reasonable assurance about whether the
consolidated financial statements are free of material misstatement. The Company
is not required to have, nor were we engaged to perform, an audit of its
internal control over financial reporting. Our audit included consideration of
internal control over financial reporting as a basis for designing audit
procedures that are appropriate in the circumstances, but not for the purpose of
expressing an opinion on the effectiveness of the Company's internal control
over financial reporting. Accordingly, we express no such opinion. An audit
includes examining, on a test basis, evidence supporting the amounts and
disclosures in the consolidated financial statements. An audit also includes
assessing the accounting principles used and significant estimates made by
management, as well as evaluating the overall consolidated financial statement
presentation. We believe that our audits provide a reasonable basis for our
opinion.

In our opinion, the consolidated financial statements referred to above
present fairly, in all material respects, the financial condition of OraLabs
Holding Corp. and Subsidiaries, as of December 31, 2004, and the results of
their operations and their cash flows for the years ended December 31, 2004 and
2003, in conformity with accounting principles generally accepted in the United
States of America.



                                             Ehrhardt Keefe Steiner & Hottman PC

April 8, 2005
Denver, Colorado

<PAGE>

                     ORALABS HOLDING CORP. AND SUBSIDIARIES
                           Consolidated Balance Sheet

                                December 31, 2004

                                     Assets
Current assets
   Cash                                                      $           866,432
   Accounts receivable, net of allowance for doubtful
    accounts of $345,177                                               1,275,820
   Inventories                                                         2,878,755
   Deferred tax asset - current                                          285,117
   Income taxes receivable                                               329,648
   Prepaid expenses                                                      264,451
   Deposits and other assets                                             158,720
                                                             -------------------
        Total current assets                                           6,058,943
                                                             -------------------

Non-current assets
   Deferred tax asset- long-term                                          45,336
   Property and equipment, net                                         1,668,675
                                                             -------------------
        Total non-current assets                                       1,714,011
                                                             -------------------

Total assets                                                 $         7,772,954
                                                             ===================

                      Liabilities and Stockholders' Equity

Current liabilities
   Accounts payable - trade                                  $           850,157
   Accrued liabilities                                                   131,812
   Reserve for returns                                                   362,342
   Current portion of long-term debt                                      12,581
                                                             -------------------
        Total current liabilities                                      1,356,892
                                                             -------------------

Non-current liabilities
   Long-term debt, less current portion                                   12,075
                                                                ----------------
        Total non-current liabilities                                     12,075
                                                             -------------------

Commitments and contingencies

Stockholders' equity
   Preferred stock, $.001 par value, 1,000,000 authorized;
    none issued and outstanding                                                -
   Common stock, $.001 par value; 25,000,000 shares
    authorized; 4,668,615 issued and 4,580,615 outstanding
    (2004) and 4,580,615 issued and outstanding (2003)                     4,669
   Additional paid-in capital                                          1,463,044
   Retained earnings                                                   4,936,274
                                                             -------------------
        Total stockholders' equity                                     6,403,987
                                                             -------------------

Total liabilities and stockholders' equity                   $         7,772,954
                                                             ===================

                 See notes to consolidated financial statements.

                                        2
<PAGE>

                     ORALABS HOLDING CORP. AND SUBSIDIARIES
                      Consolidated Statements of Operations


                                                    For the Years Ended
                                                        December 31,
                                                   2004               2003
                                        -------------------- -------------------
Product sales                           $        13,130,579  $        14,068,220
Cost of goods sold                                9,315,940            9,597,861
                                        -------------------- -------------------
        Gross profit                              3,814,639            4,470,359
                                        -------------------- -------------------

Operating expenses
   Engineering                                      319,828              250,987
   Selling and marketing                          1,325,935            1,508,649
   General and administrative                     3,047,940            2,577,568
   Other                                             32,218              348,580
                                        -------------------- -------------------
     Total operating expenses                     4,725,921            4,685,784
                                        -------------------- -------------------

Loss from operations                               (911,282)           (215,425)
                                        -------------------- -------------------

Other income (expense)
   Interest and other income                        110,965              154,056
   Other expense                                    (35,359)            (75,993)
                                        -------------------- -------------------
        Total other income (expense)                 75,606               78,063


(Loss) Income before income taxes                  (835,676)           (137,362)

Income tax benefit (expense)
   Current                                          194,648               72,245
   Deferred                                          75,920               66,339
                                        -------------------- -------------------
     Total income tax benefit                       270,568              138,584
                                        -------------------- -------------------

Net (loss) income                       $          (565,108)  $            1,222
                                        ==================== ===================

Basic weighted average common shares
 outstanding                                      4,668,615            4,580,615
                                        ==================== ===================

Basic (loss) income per common share    $             (0.12)  $             0.00
                                        ==================== ===================

Diluted weighted average common shares
 outstanding                                       4,668,615           4,580,615
                                        ==================== ===================

Diluted (loss) income per common share   $             (0.12) $             0.00
                                        ==================== ===================


                 See notes to consolidated financial statements.

                                        3
<PAGE>
<TABLE>
<CAPTION>

                     ORALABS HOLDING CORP. AND SUBSIDIARIES
            Consolidated Statement of Changes in Stockholders' Equity

                 For the Years Ended December 31, 2004 and 2003



                                                                  Additional                           Total
                                        Common Stock              Paid-in            Retained          Stockholders'
                                  Shares            Amount        Capital            Earnings          Equity
                                 ---------         --------       -----------        -----------       -----------
<S>                <C> <C>       <C>                  <C>           <C>                <C>               <C>
Balance - December 31, 2002      4,580,615            4,581         1,221,484          5,500,160         6,726,225

Net income                               -                -                 -              1,222             1,222
                                 ---------         --------       -----------        -----------       -----------
Balance - December 31, 2003      4,580,615         $  4,581       $ 1,221,484        $ 5,501,382       $ 6,727,447

Stock options exercised, net
of tax benefit                      88,000               88           241,560                              241,648

Net loss                                 -                -                 -           (565,108)         (565,108)
                                 ---------         --------       -----------         ----------       -----------
Balance - December 31, 2004      4,668,615         $  4,669       $ 1,463,044        $ 4,936,274       $ 6,403,987
                                 =========         ========       ===========        ===========       ===========

</TABLE>


                 See notes to consolidated financial statements.

                                        4
<PAGE>

                     ORALABS HOLDING CORP. AND SUBSIDIARIES
                      Consolidated Statements of Cash Flows

                                                        For the Years Ended
                                                            December 31,
                                                      2004              2003
                                                   -----------      ------------
Cash flows from operating activities
   Net (loss) income                               $ (565,108)      $     1,222
                                                   -----------      ------------
   Adjustments to reconcile net (loss) income to net
    cash provided by operating activities
     Depreciation                                     380,022           436,938
     Allowance for doubtful accounts                  (70,244)           56,221
     Deferred tax liability and asset                (151,464)          224,470
     Income tax receivable                           (194,168)                -
     Loss on sale of assets                            11,211           308,858
     Changes in assets and liabilities
       Accounts receivable - trade                    691,096          (159,856)
       Inventories                                   (456,601)         (418,610)
       Prepaid expenses and deposits                 (161,866)           10,531
       Accounts payable - trade                      (195,108)          637,566
       Accrued liabilities                            (14,519)         (158,858)
       Reserve for returns                            (34,077)         (142,699)
       Income taxes receivable (payable)              107,508          (513,077)
                                                   -----------      ------------
                                                     (88,210)          281,484
                                                   -----------      ------------
        Net cash (used in) provided by operating
         activities                                  (653,318)          282,706
                                                   -----------      ------------

Cash flows from investing activities
   Purchase of property and equipment              (1,194,484)         (376,330)

                                                   -----------      ------------
        Net cash used in investing activities      (1,194,484)         (376,330)
                                                   -----------      ------------

Cash flows from financing activities
   Payments of principal on long-term debt            (22,874)          (22,875)
   Stock options exercised                            176,000
                                                   -----------      ------------
        Net cash provided by (used in)
        financing activities                          153,126           (22,875)
                                                   -----------      ------------

Net decrease in cash                               (1,694,676)         (116,499)

Cash - beginning of year                            2,561,108         2,677,607
                                                   -----------      ------------

Cash - end of year                                 $  866,432       $ 2,561,108
                                                   ===========      ============

Supplemental disclosure of cash flow information:
Cash paid for:              Income taxes
--------------              ------------
    2004                    $     -
    2003                    $   150,000

Supplemental disclosure of non-cash transactions:

During 2004, the Company received a tax benefit of $65,648 related to the
exercise of options.

                 See notes to consolidated financial statements

                                        5
<PAGE>


Note 1 - Description of Business and Summary of Significant Accounting Policies

OraLabs Holding Corp. and Subsidiaries, (the Company), was formed in June
1997. SSI Capital Corp. (SSI) a New York Corporation was incorporated on January
30, 1981. Effective August 22, 1997, SSI was merged into the Company and the
outstanding shares of SSI were converted to shares of the Company on one-for-two
basis. In December, 2003, the Company effected a one-for-two reverse stock
split. All references to common stock in the Company's financial statements have
been retroactively adjusted for the merger and the two separate one-for-two
reductions in shares outstanding.

OraLabs Inc. (ORALABS), a Colorado corporation was incorporated on August
10, 1990. ORALABS is in the business of manufacturing and distributing lip balm,
fresh breath and other products. ORALABS is a wholly owned subsidiary of the
Company.


Principles of Consolidation

The accompanying consolidated financial statements include the accounts of
ORALABS and the accounts of SSI since the date of the reverse acquisition and
the accounts of OL Sub Corp. (an inactive entity) since inception. The Company
established a 90% owned subsidiary of OraLabs, Inc. in Brazil during 2003, with
no business activity during that year. The activity during the 2004 year was
minimal and therefore immaterial to the overall business. The Company is making
plans to close the subsidiary by the end of the 2nd quarter 2005. All
inter-company accounts and transactions have been eliminated in consolidation.


Cash and Cash Equivalents

The Company considers all highly liquid instruments purchased with an
original maturity of three months or less to be cash equivalents. The Company
continually monitors its positions with, and the credit quality of, the
financial institutions it invests with. As of the balance sheet date, and
periodically during the year, the Company has maintained balances in various
operating accounts in excess of federally insured limits.

Accounts Receivable

Accounts receivable represents receivables from customers for product
purchased. Such amounts are recorded gross of any discounts. Promotional
discounts and bad debts are estimated and accounted for in the allowance for
doubtful accounts. Management continually monitors and periodically adjusts the
allowances associated with these receivables.

Inventories

Inventories consist of raw materials, work-in-process and finished goods,
and are stated at the lower of cost or market, determined using the average cost
method.

Property and Equipment

Property and equipment is stated at cost. Depreciation is provided
utilizing the straight-line method over the estimated useful lives for owned
assets, ranging from 5 to 7 years, and the related lease terms for leasehold
improvements.

Use of Estimates

The preparation of financial statements in conformity with accounting
principles generally accepted in the United States of America requires
management to make estimates and assumptions that affect the reported amounts of
assets and liabilities, disclosures of contingent assets and liabilities at the
date of the financial statements and the reported amounts of revenues and
expenses during the reporting period. Actual results could differ from those
estimates.

Revenue Recognition

The Company recognizes revenue in accordance with the criteria set forth in
SFAS 48. Revenue is recognized as product is shipped net of estimated returns.
The Company allows for returns for defective product and records an estimate of
these returns based on historical operations and experience.

Income Taxes

The Company recognizes deferred tax liabilities and assets based on the
differences between the tax basis of assets and liabilities and their reported
amounts in the financial statements that will result in taxable or deductible
amounts in future years.

                                        6
<PAGE>

Reclassifications

Certain amounts in the 2003 consolidated financial statements have been
reclassified to conform to the 2004 presentation.

Advertising Costs

The Company expenses advertising costs as incurred.

Advertising expenses were as follows:

For the Year Ended December 31,

2004 $ 79,883
2003 $ 1,769

Research and Development Costs

Expenditures made for research and development are charged to expense as
incurred. Total research and development costs of $16,946 and $37,172 for
December 31, 2004 and 2003, respectively, were expensed in operations.

Basic and Diluted Earnings (Loss) Per Common Share

Basic Loss Per Share

The Company applies the provisions of Financial Accounting Standard No.
128, "Earnings Per Share" (FAS 128). For the years ended December 31, 2004 and
2003, The Company had 147,900 and 250,900 stock options, respectively that were
not included in the computation of earnings (loss) per share because their
effect was anti-dilutive; however, if the Company were to achieve profitable
operations in the future, they could potentially dilute such earnings.


Stock-Based Compensation

The Company has determined the value of stock-based compensation
arrangements under the provisions of APB Opinion No. 25 "Accounting for Stock
Issued to Employees"; and will make pro forma disclosures required under SFAS
No. 123, "Accounting for Stock-Based Compensation." SFAS No. 123 permits the use
of either a fair value based method of the method defined in APB No. 25 which
requires the disclosure of pro forma net income (loss) and earnings per share
that would have resulted from the use of the fair value based method.
<TABLE>
<CAPTION>


                                                                                                 December 31,
                                                                                      2004                         2003
                                                                                -----------------            ----------------

<S>                                                                               <C>                          <C>
Net (loss) income available to common shareholders-as reported                    $  (565,108)                 $  1,222
Total stock-based employee compensation expense determined under
fair market value method for an award                                                  (7,581)                   (6,098)
                                                                                       ------                    ------
Net loss available to common shareholders-pro forma                               $  (572,689)                 $ (4,876)
Basic loss per common share- as reported                                          $      0.12                  $   0.00
Basic loss per common share- pro forma                                            $      0.12                  $   0.00
</TABLE>

The fair value of each option grant is estimated on the date of grant using
the Black-Scholes option-pricing model. All option are granted at fair market
value on the date of the grant. No options have been re-priced or had their
maturities extended during 2004. In terms of the provisions of our Incentive
Option Plan, employees, with vested options, who leave the employment of the
Company, are required to exercise or forfeit their options within 90 days after
leaving employment regardless of the exercise period of the initial grant.

The following are the weighted-average assumptions used at December 31,
2004 and 2003 for all Black-Scholes calculations in the financial statements:

                                                         December 31,
                                             2004                       2003
                                           -----------               -----------
Approximate risk free rate                   3.74%                      4%
Average expected life                      5 years                 5 years
Dividend yield                                  0%                      0%
Volatility                                     73%                      73%


Recently Issued Accounting Pronouncements

In December 2004, the FASB issued SFAS 123R "share-Based Payment," a
revision to FASB No 123, SFAS 123R replaces existing requirements under SFAS No.
123 and APB Opinion NO. 25, and requires public companies to recognize a
compensation expense an amount equal to the fair value of share-based payments
granted, such as employee stock options. This is based on the grant-date fair
value of those instruments. SFAS 123R also affects the pattern in which
compensation cost is recognized, the accounting for employee share purchase
plans, and the accounting for income tax effects of share-based payment
transactions. For small-business filers such as us, SFAS 123R will be effective
for interim periods beginning after December 15, 2005. The Company is currently
determining what impact the proposed statement would have on its results of
operations and financial position. The impact will largely be due to the
selection of either the Black-Scholes or the binominal lattice model for valuing
options. The adoption of this standard, in the first quarter of 2006, will have
no impact on the Company's cash flows.

In November 2004, the FASB issued SFAS No. 151, Inventory Costs, an
amendment of ARB No. 43. This statement requires that certain abnormal costs
associated with the manufacturing, freight, and handling costs associated with
inventory be charged to current operations in the period in which they are
incurred. The Company believes the adoption of this statement will not have a
material effect on its results of operations, cash flows or financial position.


                                        7
<PAGE>

Fair Value of Financial Instruments

The carrying amounts of financial instruments including cash and cash
equivalents, receivables, prepaids, accounts payable and accrued expenses
approximated fair value as of December 31, 2004 because of the relatively short
maturity of these instruments.

Concentration of Business and Credit Risk

The Company is engaged primarily in the manufacture and sale of lip balm,
fresh breath and other products throughout North America and Internationally.
The potential for severe financial impact can result from negative effects of
economic conditions within the market or geographic area. Since the Company's
products are inexpensive, the potential negative effect of changes in economic
conditions are less than would be expected for higher priced products of other
industries.


Note 2 - Balance Sheet Disclosures

Inventories are summarized as follows at December 31, 2004:


Raw materials                                               $         1,709,459
Work in process and finished goods                                    1,169,296
                                                            -------------------
                                                            $         2,878,755
                                                            ===================



Property and equipment consist of the following at December 31, 2004:


Machinery and equipment                                     $         3,179,035
Leasehold improvements                                                  126,819
                                                            -------------------
                                                                      3,305,854
Less accumulated depreciation                                        (1,637,179)
                                                            -------------------
                                                            $         1,668,675
                                                            ===================


Note 3 - Line-of-Credit


The Company has a $2,000,000 line-of-credit with a bank secured by
substantially all of the Company's assets. The line matures in September 2005.
Interest is at a variable rate tied to LIBOR and is periodically adjusted. As of
December 31, 2004 the Company had no outstanding balance on this line-of-credit.


                                        8
<PAGE>

Note 4 - Income Taxes

The Company recognizes deferred tax liabilities and assets for the expected
future tax consequences of events that have been included in the financial
statements or tax returns. Deferred tax liabilities and assets are determined
based on the differences between the financial statement and tax basis of assets
and liabilities using the enacted tax rates in effect for the year in which the
differences are expected to reverse. The measurement of deferred tax assets is
reduced, if necessary, by the amount of any tax benefits that based on available
evidence, are not expected to be realized. As of December 31, 2004, the Company
had a Federal net operating loss ("NOL") carry forward of $204,221 that will
expire in 2024 and state net operating loss carryforwards of $982,637 that will
expire between 2023 and 2024. For the year ended December 31, 2004 the Company
will carry $572,493 of losses against prior period taxable income.

The net current and long-term deferred tax assets and liabilities in the
accompanying balance sheet include the following at December 31, 2004:

Current deferred tax asset                                  $           285,117
Current deferred tax liability                                                -
                                                             ------------------

Net current deferred tax asset                              $           285,117
                                                            ===================

Long-term deferred tax asset                                $           101,862

Long-term deferred tax liability                                        (56,526)
                                                             ------------------

Net long-term deferred tax asset                            $            45,336
                                                            ===================

Temporary differences giving rise to
a significant portion of deferred tax
Assets (liabilities) are as follows
at December 31, 2004:

Reserves for returns and other                                         151,144
Net operating loss                                                     101,862
Allowance for doubtful accounts                                        128,751
Contributions carried forward
5,222
                                                            -------------------
Total deferred tax asset                                    $          386,979
                                                            ===================

Property and equipment                                      $          (56,526)

                                                            -------------------
Total deferred tax liability                                $          (56,526)
                                                            ===================

Net deferred tax asset                                      $          330,453
                                                            ===================

The following is a reconciliation of the statutory federal income tax rate
applied to pre-tax accounting net income compared to the income taxes in the
consolidated statements of income:

                                                          For the Years Ended
                                                              December 31,
                                                             2004        2003
                                                       ------------ -----------
Income benefit at the
 statutory rate                                         $ (284,129)  $ (51,510)

Change resulting from:
   State and local income taxes, net of
   federal income tax                                      (27,516)          -
   Non-deductible expenses                                     713         638
   Foreign tax credits and income
    exclusions                                             (22,739)    (87,712)
   Other                                                    63,103
                                                       ------------ ------------
                                                         $(270,568)  $(138,584)
                                                       ============ ============

                                        9
<PAGE>

Note 5 - Long-Term Debt

At December 31, 2004 long-term debt consists of:


Note payable to a financing company with interest
 at 0%. The note calls for monthly principal
 payments of $1,381 and matures May 2005. Collateralized
 by a vehicle.                                                       $    5,756

Note payable to a financing company with interest at 0%.
 The note calls for monthly principal payments of $525
 and matures December 2007. Collateralized by vehicle.                   18,900
                                                                     ----------
                                                                         24,656
         Less current portion                                           (12,581)
                                                                     ----------
                                                                     $   12,075
                                                                     ==========



Maturities of long-term obligations are as follows:



Year Ending December 31,
------------------------
            2005                                                      12,581
            2006                                                       6,300
            2007                                                       5,775

                                                         -------------------
                                                         $            24,656
                                                         ===================



                                       10
<PAGE>

Note 6 - Commitments and Contingencies

Related Party Operating Leases

The Company leases office and manufacturing facilities under separate
operating leases for buildings owned or controlled by the Company's president.

The Company also has one operating lease outstanding for a vehicle.

Rent expense for these leases was:

Year Ending December 31,

2004 $ 529,859
2003 $ 280,438



Future minimum lease payments under these leases are approximately as follows:

Year Ending December 31,
------------------------



2005                  451,000
2006                  335,000
                   ----------
                   $  786,000
                   ==========


During 2003, the Company abandoned certain leasehold improvements located
within the two Englewood, Colorado facilities leased from the Company's
President and majority stockholder or his affiliate. The loss on abandonment was
approximately $308,000 and is included in other operating expenses.

Litigation

ORALABS is a party to a legal proceeding that was brought in the Circuit
Court of the First Judicial District of Heinz County, Mississippi that was
served on the Company on February 26, 2004. The litigation was brought by
individuals who allege that a five-year-old child ingested a portion of a bottle
that allegedly was manufactured by ORALABS for one of its products. The product
was not specified in the complaint. The complaint alleges that the minor child
suffered permanent injuries and damages as a result of the ingestion of the
portion of the bottle, and the plaintiffs claim compensatory damages in an
unstated amount and punitive damages in the amount of $1,925,000. ORALAB'S
insurance company is tendering a defense. Punitive damages, however, are not
covered by the insurance policy. ORALABS intends to vigorously defend the suit
and believes that it has no liability to the plaintiffs. ORALABS further
believes that even if liability is assessed against it, any compensatory damages
assessed will be covered by its insurance policy. The Company believes that the
possibility of any award of punitive damages against it is very remote. However,
if a significant uninsured judgment is awarded against ORALABS, it could put an
extreme financial strain upon it.


Deposit

At December 31, 2004 and 2003, the Company had deposits of approximately
$158,720 and $117,620, respectively for orders of production materials.

Note 7 - Stockholders' Equity

Stock Options

In 1997, the Company adopted an incentive stock option plan for employees.
Under this plan, the board approved a program to grant certain employees the
right to purchase common stock of the Company for $2.00 per share. The options
vest on an annual basis. As of December 31, 2004, the Company had 105,400
incentive options outstanding under this plan, each with an exercise price of
$2.00 per share.

In September 1997, the Company adopted a Non-Employee Directors' Option
Plan. The Board approved a program to grant certain directors the right to
purchase common stock of the Company. The options vest on an annual basis. As of
December 31, 2004, the Company had 42,500 options outstanding under this plan
with exercise prices ranging from $1.32 to $5.00.

All of the following prices and numbers of shares have been adjusted to
give effect to the one-for-two reverse stock split adopted by the Company on
December 16, 2003.

                                       11
<PAGE>

The following table presents the activity for options outstanding:



                                        Incentive      Non-qualified    Average
                                        Stock          Stock            Exercise
                                        Options        Options          Price
                                        ----------     -------------    --------
Outstanding - December 31, 2002          218,400          37,500           2.30
         Granted                               -           7,500           1.23
         Forfeited/canceled               (7,500)         (5,000)          2.00
         Exercised                             -               -              -
                                         --------         -------        -------

Outstanding - December 31, 2003          210,900          40,000        $  2.15
         Granted                                           7,500           1.79
         Forfeited/canceled              (17,500)         (5,000)          2.22
         Exercised                       (88,000)                          2.00
                                         --------         -------        -------
Outstanding - December 31, 2004          105,400          42,500        $  2.15
                                         ========         =======        =======




The following table presents the composition of options outstanding and
exercisable:
<TABLE>
<CAPTION>



                                             Options Outstanding                                Options Exercisable
     Range of Exercise Prices             Number           Price*             Life*           Number            Price*
----------------------------------   ---------------- ----------------  ---------------- ----------------  -----------
<S>     <C>                               <C>         <C>                      <C>             <C>         <C>
$1.32 - $1.79                             15,000      $       1.56             4.00            1,875       $     1.32
$2.00                                    105,400              2.00             2.63          105,400             2.00
$2.01 - $3.00                             20,000              2.42             1.17           16,250             2.41
$3.01 - $5.00                              7,500              4.75             1.42            5,625             4.75
                                     ---------------- ----------------  ---------------- ----------------  ----------------

Total - December 31, 2004                147,900      $       2.15             2.51          129,150       $     2.15
                                     ================ ================  ================ ================  ================

</TABLE>

* Price and life reflect the weighted average exercise price and weighted
average remaining contractual life, respectively.


                                       12

<PAGE>






Note 8 - Income Per Share

The following table sets forth the computation for basic and diluted
earnings per share:



                                                         For the Years Ended
                                                             December 31,
                                                          2004          2003
                                                     -------------- ------------
Numerator for basic earnings per share               $   (565,108)  $     1,222
                                                     ============= =============

Numerator for diluted income per common share        $   (565,108)  $     1,222
                                                     ============= =============

Denominator for basic earnings per share -
 weighted average shares                                4,668,615     4,580,615
Effect of dilutive securities - options                        -
                                                     ------------- -------------
Denominator for diluted earnings per share -
 adjusted weighted average shares                       4,668,615     4,580,615
                                                     ============= =============

Diluted (loss) income per common share               $      (0.12)  $      0.00
                                                     ============= =============



Where the inclusion of potential common shares is anti-dilutive, such
shares are excluded from the computation.

Note 9 - Definitive Agreement

OraLabs entered into a Definitive Agreement with NVC Lighting Investment
Holdings Limited under which OraLabs will acquire NVC and convey its ownership
of OraLabs, Inc. to OraLabs' President, Gary H. Schlatter. Control of the
Company would change from Mr. Schlatter to the owners of NVC. Closing under the
Definitive Agreement is conditioned upon many requirements and there can be no
assurance that the closing will occur. If the parties do not otherwise terminate
the Definitive Agreement, then OraLabs, in anticipation of a meeting of its
shareholders called to approve the transactions, will file with the Securities
and Exchange Commission a Proxy Statement that will include more detailed
information about the Definitive Agreement and the proposed transactions.

                                       13
<PAGE>

Note 10 - Major Customers

The Company had two major customers that accounted for net sales of
approximately $1,950,000 and $1,400,000, respectively, of which $174,805 was due
from these customers and included in accounts receivable at year end. For the
year ended December 31, 2003, two customers accounted for net sales of
approximately $1,644,000 and $1,199,000, respectively, of which $594,000 was due
from those customers and included in accounts receivable at December 31, 2003.

Note 11 - Export Sales

During the year ended December 31, 2004 and 2003, the Company had export
sales of approximately $918,000 and $870,175, or 7% and 6% of product sales,
respectively. All of the Company's export business is transacted in U.S. dollars
and the Company had no foreign currency translation adjustments.

Note 12 - Significant Fourth Quarter Adjustments

In the fourth quarter for the year ended December 31, 2004, the Company
made the following adjustments to the financial statements:

The Company expensed $38,285 related to expansion opportunities in South
America.

The Company adjusted its inventory valuation as a result of its year-end
physical inventory and the audit of raw material costs. The audit adjustment
increased inventory valuation by $121,155.


Note 13- 401K Plan


During 2004, the Company began to offer a 401(k) retirement plan (the
"Plan") which covers all employees. Employees are eligible to participate after
one year of service. Employees may contribute amounts based on the limits
established by the Internal Revenue Service. Employer discretionary payments, as
well as certain matching contributions, may be made as determined by the Board
of Directors. The discretionary and matching contributions vest immediately.
During 2004, the Company contributed approximately $61,000 to the Plan.

                                       14
<PAGE>

                                  EXHIBIT INDEX



Exhibit
No.      Description
--------------------

14.1     Code of Ethics
23.1     Consent of Independent Registered Public Accounting Firm (Ehrhardt
               Keefe, Steiner & Hottman P.C.)
31.1     Certification Pursuant To 18 U.S.C. Section 1350, As Adopted Pursuant
               To Section 302 Of The Sarbanes-Oxley Act Of 2002
31.2     Certification Pursuant To 18 U.S.C. Section 1350, As Adopted Pursuant
               To Section 302 Of The Sarbanes-Oxley Act Of 2002
32.1     Certification pursuant to 18 U.S.C. Section 1350, as adopted
               pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, by
               Emile Jordan
32.2     Certification pursuant to 18 U.S.C. Section 1350, as adopted
               pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, by
               Gary H. Schlatter